Briefing Note

Why claims drift after evidence review

A claim is written once. The evidence under it keeps moving. The gap that opens between them is predictable in shape but not in timing — and the thing that usually closes it is an authority publishing something.

Claims don’t stay put

A claim is supported at the moment it is written. Trial data, guideline language, label updates, payer policies, and real-world evidence continue to change after that moment. The claim does not update itself.

The gap between what the evidence now supports and what the claim asserts is claim drift. It is structural: claims are written once, evidence changes continuously.

Where drift happens

Most teams encounter claim drift when:

• A payer deck overstates a subgroup finding. The original trial showed benefit in the full cohort. A subgroup analysis looked promising but did not meet statistical significance. The deck presents it as established fact.
• A guideline changes but the claim bank is not updated. The guideline committee narrows a recommendation. The internal claim repository still carries the older, broader language into payer conversations.
• MLR-cleared assets keep using outdated evidence. A label update or guideline change narrows the supported population. The MLR-approved materials were cleared before the update and have not been reviewed against the updated evidence.
• A formulary argument broadens beyond the studied population. An access argument for one indication is reused for a related indication without confirming the evidence trail.
• A review memo relies on an endpoint that later weakens. A new trial readout shows that a secondary endpoint no longer reaches significance. The memo is still in circulation.

Why episodic review misses it

Most organizations review claims on a schedule: quarterly P&T meetings, annual guideline updates, pre-launch review. Between reviews, evidence accumulates — new trial results, label changes, payer policy shifts.

By the time the review convenes, the claim is already unsupported. The committee is confirming a position that the evidence no longer holds. The longer the gap between reviews, the more drift accumulates.

What a drift check actually asks

Whatever form the review takes, it comes down to the same seven questions:

• Does the stated population still match the evidence population?
• Is the comparator still relevant under current practice?
• Do the endpoints still carry the weight the claim assigns them?
• Are the caveats from the original publication still attached?
• Has the claim broadened beyond what the source record supports?
• Have label changes or guideline updates narrowed the supported scope?
• Does the claim still hold under the most recent guideline language?

The cost of not checking

When an unsupported claim makes it into a payer deck, MLR review, formulary submission, or review memo, the cost is not just rework. It is delayed launch timelines, payer pushback, compliance exposure, and loss of reviewer trust in the evidence function.

The review itself becomes harder: the team must reconstruct what the evidence supported at the time the claim was written, then compare it to what the evidence supports now, then decide whether the claim is still supportable as written. This is slow, error-prone, and unrepeatable without a record of what changed.

Reviewing more often does not fix it

Shortening the review cycle reduces how much drift accumulates between checks. It does not tell you which claims are about to need attention, so the extra reviews land uniformly across a portfolio where the risk is not uniform at all. Most of that work confirms claims that were never in danger.

The events that actually invalidate a claim — a guideline narrowing a recommendation, a label restricting a population, a payer tightening coverage — are decisions by named bodies, taken on published calendars, and visible in the public record well before they land. That is the part worth forecasting. Knowing which authority is likely to move, and roughly when, tells you which claims to pull forward and which to leave alone.

Name the guideline, regulatory, or coverage action that would undermine the claim, and the date you would need to know by. Whether that transition can be forecast at all is the first question, and it is answerable before anyone relies on the answer.